“The most dangerous thing in business is not failure. It is building the right thing at the wrong altitude.”
The Hypothesis
In 2016, I walked out of Yale with a conviction. Not a battle-tested business plan — a conviction. I believed that if you put a drug quality testing tool in the hands of pharmacists at the point of sale, you could reduce the flow of counterfeit medicines into low-income communities. The idea was born from lived experience, not market research. I had seen families buy medicines that did not work. I had watched the human cost of broken supply chains.
We built an AI-powered spectrometer — a device that uses machine learning and spectroscopy to authenticate drugs in seconds. The technology worked. The hypothesis was sound. But the business was dying.
The Struggle
From 2016 to 2020, we pushed. We earned acceptance into G-Startup Worldwide, won the Hello Tomorrow DeepTech Prize, completed Shenzhen, raised early funding from SOSV and Katapult. The press covered us. The prize committees recognized us.
And adoption stayed below 5%.
Here is what I learned in those four years: pharmacists did not wake up thinking about drug quality testing. They woke up thinking about cash flow, inventory, insurance reimbursements, and foot traffic. Drug quality was important — but it sat on a list of twenty problems. We were asking them to adopt a tool that solved problem number seventeen.
That is not a technology problem. That is an altitude problem. We were building at the product level. We needed to build at the infrastructure level.
The Catalyst
In early 2020, COVID-19 shut the world down. Pharmacies — particularly the hundreds already using our device — called us in desperation. Not about drug quality. About survival. They needed digital storefronts. They needed a way to sell remotely, manage inventory from home, and reach patients who could not visit in person.
We did not fail. We listened.
That wave of calls rewired our thinking. We stopped being a drug authentication company with a device. We became a pharmacy workflow automation platform with an AI spectrometer embedded inside it.
The Rebuild
Once we understood that the spectrometer was a feature — not the product — we redesigned the entire architecture around the daily reality of running a pharmacy. Here is what the platform became:
A. AI-powered drug quality testing automation — the original spectrometer, now embedded seamlessly into the procurement workflow rather than standing alone.
B. Inventory management automation — AI-driven tracking that eliminates manual stock counts and reduces waste.
C. Health insurance reimbursement automation — processing claims faster so pharmacies get paid on time, every time.
D. Patient lead generation and AI ordering — online storefronts for each pharmacy in our network, an AI agent that helps patients order based on available stock, and connections to prescribing doctors who know what the pharmacy carries.
E. Business training and systems orchestration — equipping healthcare professionals with operational skills, not just clinical ones, and coordinating the delivery network for fulfillment.
F. Supply chain financing — providing pharmacies the working capital to buy directly from our vetted supplier network, cutting out the low-quality middlemen. AI automates credit assessment, stockout forecasting enables predictive reordering by region, and anonymous reporting flags substandard brands and suppliers to regulators.
This is not six products. This is one system — designed so that every layer reinforces every other layer. The more a pharmacy uses, the more value it captures. The more value it captures, the harder it is to leave.
The Result
Adoption moved from 5% to 92%.
Not because we made a better spectrometer. Because we made the pharmacy more profitable. We became the operating system for their business.
Today, RxAll is a workflow automation platform for over 10,000 pharmacies. We hold primary data on what more than 5 million patients consume monthly in terms of medications. We provide our big pharma partners with direct access to prescribers and healthcare practitioners. We have maintained a 99.5% retention rate over the past 24 months.
We have been profitable for five consecutive years. We operate growing businesses in the United States and across multiple global markets. We have a clear pathway to going public when the timing is right.
Some investors look at us and see complexity. What they are actually seeing is a handcuff business — a platform so embedded in daily pharmacy operations that the cost of leaving exceeds the cost of staying by a factor of ten.
The Lesson
Here is what I want every founder building in healthcare, fintech, or any operationally complex market to understand:
A product can be replaced overnight. Infrastructure takes years to replicate.
If your customers use your tool once a week, you are a product. If they use your system every hour of every day — for ordering, selling, stocking, financing, reporting, and training — you are infrastructure. And infrastructure does not churn.
The pivot that saved RxAll was not a pivot away from our mission. It was a pivot in altitude. We stopped selling a device. We started building a system. We stopped asking pharmacies to care about drug quality in isolation. We made drug quality a byproduct of running a better business.
A product solves a problem. A platform solves a business.
Onwards.
Adebayo Alonge is the Founder and Group CEO of RxAll Group. A Harvard Kennedy School Mason Fellow, Yale School of Management alumnus, and MIT Legatum Fellow, he builds AI-powered platforms that deliver healthcare, capital, and clean energy to underserved markets worldwide. He has raised $11M+ from Tier 1 VCs, driven $180M+ in product sales, and serves millions of patients monthly. He is a Fast Company World Changing Ideas 2025 honoree and winner of the Hello Tomorrow DeepTech Prize.
#AIHealthcare #DeepTech #StartupPivot #PharmacyAutomation #ArchitectOfOrder
Discover more from Adebayo Alonge
Subscribe to get the latest posts sent to your email.
